Animal models of schizophrenia
- PMID: 21449915
- PMCID: PMC3229756
- DOI: 10.1111/j.1476-5381.2011.01386.x
Animal models of schizophrenia
Abstract
Developing reliable, predictive animal models for complex psychiatric disorders, such as schizophrenia, is essential to increase our understanding of the neurobiological basis of the disorder and for the development of novel drugs with improved therapeutic efficacy. All available animal models of schizophrenia fit into four different induction categories: developmental, drug-induced, lesion or genetic manipulation, and the best characterized examples of each type are reviewed herein. Most rodent models have behavioural phenotype changes that resemble 'positive-like' symptoms of schizophrenia, probably reflecting altered mesolimbic dopamine function, but fewer models also show altered social interaction, and learning and memory impairment, analogous to negative and cognitive symptoms of schizophrenia respectively. The negative and cognitive impairments in schizophrenia are resistant to treatment with current antipsychotics, even after remission of the psychosis, which limits their therapeutic efficacy. The MATRICS initiative developed a consensus on the core cognitive deficits of schizophrenic patients, and recommended a standardized test battery to evaluate them. More recently, work has begun to identify specific rodent behavioural tasks with translational relevance to specific cognitive domains affected in schizophrenia, and where available this review focuses on reporting the effect of current and potential antipsychotics on these tasks. The review also highlights the need to develop more comprehensive animal models that more adequately replicate deficits in negative and cognitive symptoms. Increasing information on the neurochemical and structural CNS changes accompanying each model will also help assess treatments that prevent the development of schizophrenia rather than treating the symptoms, another pivotal change required to enable new more effective therapeutic strategies to be developed.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.
Figures
Similar articles
-
[Cognition, schizophrenia and the effect of antipsychotics].Encephale. 2006 May-Jun;32(3 Pt 1):341-50. doi: 10.1016/s0013-7006(06)76162-0. Encephale. 2006. PMID: 16840928 Review. French.
-
[Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].Encephale. 2008 Dec;34(6):557-62. doi: 10.1016/j.encep.2007.12.005. Epub 2008 Jul 9. Encephale. 2008. PMID: 19081451 French.
-
[Cognitive deficits in first episode psychosis patients and people at risk for psychosis: from diagnosis to treatment].Encephale. 2013 May;39 Suppl 1:S64-71. doi: 10.1016/j.encep.2012.10.011. Epub 2013 Mar 23. Encephale. 2013. PMID: 23528322 Review. French.
-
Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers.Schizophr Res. 2005 Sep 1;77(1):43-58. doi: 10.1016/j.schres.2004.12.019. Schizophr Res. 2005. PMID: 16005384 Clinical Trial.
-
Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.Eur Neuropsychopharmacol. 2016 Jan;26(1):3-14. doi: 10.1016/j.euroneuro.2015.11.016. Epub 2015 Nov 19. Eur Neuropsychopharmacol. 2016. PMID: 26655189
Cited by
-
The atypical antipsychotic risperidone reverses the recognition memory deficits induced by post-weaning social isolation in rats.Psychopharmacology (Berl). 2013 Jul;228(1):31-42. doi: 10.1007/s00213-013-3011-2. Epub 2013 Feb 9. Psychopharmacology (Berl). 2013. PMID: 23397053
-
Drug models of schizophrenia.Ther Adv Psychopharmacol. 2015 Feb;5(1):43-58. doi: 10.1177/2045125314557797. Ther Adv Psychopharmacol. 2015. PMID: 25653831 Free PMC article. Review.
-
The Role of Amino Acids in Neurotransmission and Fluorescent Tools for Their Detection.Int J Mol Sci. 2020 Aug 27;21(17):6197. doi: 10.3390/ijms21176197. Int J Mol Sci. 2020. PMID: 32867295 Free PMC article. Review.
-
Assessing olfactory, memory, social and circadian phenotypes associated with schizophrenia in a genetic model based on Rim.Transl Psychiatry. 2021 May 17;11(1):292. doi: 10.1038/s41398-021-01418-3. Transl Psychiatry. 2021. PMID: 34001859 Free PMC article.
-
A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice.Transl Psychiatry. 2015 Feb 17;5(2):e512. doi: 10.1038/tp.2015.2. Transl Psychiatry. 2015. PMID: 25689573 Free PMC article.
References
-
- Abdul-Monim Z, Reynolds GP, Neill JC. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res. 2006;169:263–273. - PubMed
-
- Abdul-Monim Z, Neill JC, Reynolds GP. Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J Psychopharmacol. 2007;21:198–205. - PubMed
-
- Abekawa T, Honda M, Ito K, Inoue T, Koyama T. Effect of MS-153 on the development of behavioral sensitization to locomotion- and ataxia-inducing effects of phencyclidine. Psychopharmacology (Berl) 2002;160:122–131. - PubMed
-
- Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR, et al. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry. 1999;156:1580–1589. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical